
    
      This trial is a prospective, multi-center, single-arm First-In-Man Continuation study to
      evaluate safety and efficacy of the VenTouch System for treatment of subjects with functional
      MR enrolling up to 15 subjects who have been diagnosed with Grade 3-4 functional mitral valve
      regurgitation. The duration of the study follow-up is 36 months from the time of therapy
      adjustment. Data from this trial may be utilized in support of a CE study in Europe and/or a
      pilot IDE study in the U.S. Follow-up testing will be performed at 1 month, 3 months, 6
      months, and 12, 24, and 36 months post-therapy adjustment.
    
  